Medical Pharmacology: -- Module: LD-03 — Statins: Adverse Effects, Monitoring, and Special Populations

— Module: LD-03 — Statins: Adverse Effects, Monitoring, and Special Populations
Tier: T3 — Clinical Vignettes

1. A 58-year-old man with established coronary artery disease is started on simvastatin 40 mg daily. Six weeks later he develops proximal muscle aching and his creatine kinase (CK) is measured at 8× the upper limit of normal (ULN). He takes no interacting medications. Pharmacogenomic testing reveals he is homozygous for the solute carrier organic anion transporter 1B1 (SLCO1B1) 521T>C variant (rs4149056). Which of the following best explains the mechanism by which this variant increased his risk of myopathy?

A) The variant upregulates cytochrome P450 3A4 (CYP3A4) activity in the liver, accelerating simvastatin conversion to its active acid form and producing supratherapeutic tissue concentrations.
B) The variant encodes a structurally abnormal HMG-CoA reductase enzyme that is hypersensitive to competitive inhibition by simvastatin, amplifying the degree of mevalonate pathway blockade in skeletal muscle.
C) The variant reduces hepatic uptake of simvastatin via impaired organic anion-transporting polypeptide 1B1 (OATP1B1) transporter function, resulting in higher systemic plasma concentrations and greater skeletal muscle exposure.
D) The variant impairs mitochondrial coenzyme Q10 (CoQ10) synthesis in skeletal muscle, reducing oxidative phosphorylation capacity and creating an energy deficit that sensitizes myocytes to statin-mediated injury.
E) The variant produces a gain-of-function mutation in the multidrug resistance protein 2 (MRP2) efflux transporter, preventing biliary excretion of simvastatin and causing hepatic accumulation with secondary myotoxic metabolite release.

ANSWER: C

Rationale:

The SLCO1B1 gene encodes the organic anion-transporting polypeptide 1B1 (OATP1B1) hepatic uptake transporter, which is responsible for extracting statins from portal blood into hepatocytes — the site of both therapeutic action (HMG-CoA reductase inhibition in the liver) and first-pass elimination. The 521T>C variant (rs4149056) reduces OATP1B1 transporter activity, impairing hepatic uptake of simvastatin. The consequence is a shift in the pharmacokinetic profile: less drug reaches the liver (where the therapeutic effect occurs) and more remains in systemic circulation, increasing skeletal muscle exposure. This unfavorable shift in the therapeutic index — reduced hepatic delivery relative to systemic exposure — directly increases myopathy risk. The variant is the strongest known pharmacogenomic predictor of statin-associated muscle symptoms and is particularly relevant for simvastatin, which has high OATP1B1 dependence for hepatic uptake. Homozygosity for the 521C allele confers substantially greater risk than heterozygosity.

Option A: Option A is incorrect because the SLCO1B1 variant does not affect CYP3A4 activity; CYP3A4 governs simvastatin metabolism but is encoded by separate genes (CYP3A4, CYP3A5).
Option B: Option B is incorrect because the variant affects a transporter protein, not HMG-CoA reductase itself; the enzyme's sensitivity to competitive inhibition is not altered by SLCO1B1 genotype.
Option D: Option D is incorrect because CoQ10 depletion is a proposed downstream consequence of HMG-CoA reductase inhibition (via isoprenoid pathway blockade), not a direct effect of the SLCO1B1 variant; furthermore, randomized trials of CoQ10 supplementation have not demonstrated consistent benefit for statin-associated muscle symptoms, suggesting CoQ10 depletion alone is not the dominant myotoxic mechanism.
Option E: Option E is incorrect because MRP2 is a biliary efflux transporter encoded by the ABCC2 gene, not SLCO1B1; gain-of-function MRP2 variants would increase biliary excretion rather than reduce it, and this mechanism has no established role in statin-associated myopathy.

2. A 64-year-old woman with hyperlipidemia was taking atorvastatin 40 mg daily for three years before developing progressive proximal leg weakness and difficulty rising from a chair. Her creatine kinase (CK) is 12,000 units/L (reference <200 units/L). Atorvastatin is discontinued, but six weeks later her weakness has worsened and CK remains at 9,800 units/L. Which of the following is the most appropriate next diagnostic step?

A) Test for anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) antibodies and refer to a neuromuscular specialist.
B) Rechallenge with rosuvastatin 5 mg every other day and recheck CK in four weeks to confirm statin causality before pursuing further workup.
C) Obtain a thyroid-stimulating hormone (TSH) level and vitamin D level, as hypothyroidism and vitamin D deficiency are the most common causes of persistent CK elevation after statin discontinuation.
D) Proceed directly to muscle biopsy without serological testing, as antibody assays have insufficient sensitivity to guide management in statin-associated autoimmune myopathy.
E) Initiate high-dose corticosteroids empirically without further workup, as the clinical presentation is diagnostic of statin-associated autoimmune myopathy (SAAM) and delay increases the risk of irreversible muscle damage.

ANSWER: A

Rationale:

The clinical picture — proximal muscle weakness developing after years of statin use, markedly elevated CK (>40× ULN), and failure to improve (in fact worsening) six weeks after statin discontinuation — is the defining presentation of statin-associated autoimmune myopathy (SAAM), an immune-mediated necrotizing myopathy that is categorically distinct from ordinary statin-associated muscle symptoms (SAMS). The cardinal distinguishing feature is that weakness and CK elevation persist or worsen after statin cessation, in contrast to pharmacological SAMS, which typically resolves within four to six weeks of discontinuation. The most appropriate next step is serological testing for anti-HMG-CoA reductase (HMGCR) antibodies — the defining serological marker present in approximately 60 to 70 percent of cases — combined with referral to a neuromuscular specialist for electromyography and consideration of muscle biopsy. This workup confirms the diagnosis, guides immunosuppressive therapy selection, and establishes a baseline for monitoring treatment response.

Option B: Option B is incorrect and dangerous: rechallenge with any statin is contraindicated in suspected SAAM. Statin re-exposure in a patient with immune-mediated necrotizing myopathy can exacerbate the autoimmune process.
Option C: Option C is incorrect because while hypothyroidism and vitamin D deficiency are relevant risk factors for ordinary SAMS, they do not explain persistent worsening after statin discontinuation at this CK magnitude; TSH and vitamin D testing may be part of a broader workup but are not the most appropriate next step in this presentation.
Option D: Option D is incorrect because anti-HMGCR antibody testing has well-established clinical utility and is the recommended initial serological test; proceeding directly to muscle biopsy without serological evaluation delays diagnosis and is not consistent with current diagnostic pathways.
Option E: Option E is incorrect because empirical immunosuppression without confirming the diagnosis risks treating an alternative condition (polymyositis, dermatomyositis, hypothyroid myopathy, inclusion body myositis) inappropriately; serological and histological confirmation should precede immunosuppressive therapy initiation in all but the most emergent presentations.

3. A 52-year-old man with a history of myocardial infarction reports muscle aching and fatigue that began shortly after starting atorvastatin 40 mg daily four months ago. He is convinced the statin is causing his symptoms and has already discontinued it twice on his own. His CK on two occasions has been normal. He is enrolled in the Self-Assessment Method for Statin Side-effects Or Nocebo (SAMSON) trial protocol — a double-blind n-of-1 crossover design in which he alternates monthly between blinded atorvastatin and identical placebo capsules. At the end of the study period, his muscle symptom scores during the statin months and placebo months are nearly identical. Which of the following conclusions is most directly supported by this result?

A) The patient has confirmed statin-associated myopathy and should be switched to a hydrophilic statin such as rosuvastatin or pravastatin to reduce muscle penetration.
B) The patient's symptoms are entirely psychosomatic and he should be reassured that statins cause no muscle symptoms in any patient at standard doses.
C) The patient's CK-negative muscle symptoms are most likely attributable to an alternative systemic diagnosis such as fibromyalgia or inflammatory myositis that warrants rheumatological referral.
D) The majority of the patient's reported muscle symptom burden is attributable to the nocebo effect rather than to the pharmacological action of the statin, and rechallenge with informed counseling is appropriate.
E) The crossover design is methodologically flawed because carryover effects from atorvastatin's long half-life invalidate the placebo months, and the result cannot be interpreted.

ANSWER: D

Rationale:

The SAMSON trial (2020) was a randomized, double-blind n-of-1 crossover study specifically designed to quantify the relative contributions of pharmacological statin action versus the nocebo effect to muscle symptoms in patients with prior self-reported statin intolerance. The key finding was that approximately 90 percent of the muscle symptom intensity reported during statin months was replicated during placebo months — meaning the vast majority of symptom burden arose from negative expectation (nocebo effect) rather than from statin pharmacology. When a patient's symptom scores are nearly identical on blinded statin and blinded placebo, the most direct conclusion is that pharmacological statin action is not the primary driver of symptoms, and that the nocebo component dominates. This finding has direct and actionable clinical implications: the patient is a strong candidate for successful rechallenge if the nocebo component is addressed through patient education, informed re-exposure, and shared decision-making about the cardiovascular risk of remaining off statin therapy.

Option A: Option A is incorrect because normal CK and symptom equivalence on placebo do not confirm statin-associated myopathy; switching statin type is not indicated when the nocebo mechanism is the dominant contributor.
Option B: Option B is incorrect because the SAMSON findings do not establish that statins cause no muscle symptoms — they quantify the nocebo contribution as dominant in this population of prior statin-intolerant patients; a minority of symptom burden was attributable to statin pharmacology.
Option C: Option C is incorrect because the n-of-1 crossover result provides a more parsimonious and direct explanation — nocebo effect — without requiring referral for alternative diagnoses when no other features of fibromyalgia or inflammatory myositis are present.
Option E: Option E is incorrect because the SAMSON trial design specifically accounted for washout periods between statin and placebo months to address carryover; furthermore, atorvastatin's half-life of approximately 14 hours is short enough that meaningful carryover across monthly periods is not a valid methodological objection.

4. A 61-year-old woman with type 2 diabetes mellitus and a 10-year ASCVD risk of 18% is started on rosuvastatin 20 mg daily. Her baseline alanine aminotransferase (ALT) is normal. She is otherwise asymptomatic and her liver examination is unremarkable. She asks how often her liver function tests should be checked while she is on the statin. Which of the following best reflects current evidence-based monitoring guidance?

A) ALT should be checked every three months for the first year, then every six months thereafter, as dose-dependent hepatocellular injury is common with moderate-to-high intensity statins and requires surveillance to prevent progression to liver failure.
B) Routine periodic ALT monitoring is not recommended after a normal baseline; follow-up liver testing should be prompted only by symptoms suggestive of hepatotoxicity such as jaundice, right upper quadrant pain, or dark urine.
C) ALT should be rechecked at six weeks after initiation to detect early transaminase elevation, then annually thereafter regardless of symptoms, as asymptomatic elevation predicts the rare patient who will progress to clinical hepatitis.
D) Liver function tests should be obtained at baseline and repeated only if the dose is increased, because dose escalation — not time on therapy — is the primary driver of statin-associated hepatocellular injury.
E) No liver function testing is required at any point, including before initiation, because large randomized trials have established that statins have no hepatotoxic potential at approved doses.

ANSWER: B

Rationale:

In 2012, the FDA revised the prescribing information for all approved statins to eliminate the requirement for routine periodic liver function test monitoring during statin therapy. This revision was based on the conclusion that routine monitoring does not detect or prevent serious liver injury and that the incidence of true clinically significant statin hepatotoxicity is sufficiently low — estimated at approximately 1 to 3 per 100,000 patient-years — that it does not justify the clinical burden, patient anxiety, and unnecessary statin discontinuation generated by routine surveillance. Current ACC/AHA and FDA guidance recommends obtaining a baseline ALT before initiating statin therapy, then performing follow-up liver testing only when the patient develops symptoms suggestive of hepatotoxicity (jaundice, right upper quadrant pain, fatigue, dark urine) or when baseline liver disease is present. Asymptomatic and self-limited ALT elevations above 3× the upper limit of normal (ULN) occur in approximately 0.5 to 3 percent of statin-treated patients, are dose-dependent, and typically resolve spontaneously — they do not predict progression to clinical hepatitis or liver failure and do not require routine detection.

Option A: Option A is incorrect because it describes the outdated pre-2012 monitoring paradigm that was specifically abandoned based on evidence; quarterly or biannual routine monitoring is not consistent with current guidance.
Option C: Option C is incorrect because asymptomatic transaminase elevations do not reliably predict clinical hepatitis progression and surveillance-directed follow-up is not recommended under current guidelines.
Option D: Option D is incorrect because while the baseline ALT is recommended, dose-escalation-triggered retesting is not the standard framework articulated in current guidance; the correct trigger is symptom development, not dose change.
Option E: Option E is incorrect because baseline liver function testing before initiation is recommended, and the claim that statins have no hepatotoxic potential is an overstatement — true statin-associated drug-induced liver injury (DILI) exists, albeit at very low incidence.

5. A 49-year-old man with metabolic syndrome, a body mass index (BMI) of 33 kg/m², and a fasting glucose of 108 mg/dL (impaired fasting glucose) is started on atorvastatin 80 mg daily for an LDL-cholesterol of 168 mg/dL and a calculated 10-year ASCVD risk of 14%. Eighteen months later his fasting glucose is 128 mg/dL and he is diagnosed with type 2 diabetes mellitus. His cardiologist notes that statin therapy likely contributed to this development. Which of the following mechanisms best explains statin-associated new-onset diabetes mellitus?

A) Statins activate peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue, promoting lipid storage and adipokine dysregulation that secondarily impairs hepatic insulin sensitivity.
B) Statins competitively inhibit glucokinase in pancreatic beta cells, preventing glucose sensing and abolishing the glucose-stimulated insulin secretion response entirely.
C) Statins directly damage pancreatic beta cell mitochondria through reactive oxygen species (ROS) generation, causing irreversible beta cell apoptosis proportional to cumulative statin dose.
D) Statins induce sodium-glucose cotransporter 2 (SGLT2) upregulation in the renal proximal tubule, increasing glucose reabsorption and raising fasting plasma glucose independent of insulin resistance.
E) Statins reduce glucose transporter type 4 (GLUT4) expression in skeletal muscle and adipose tissue and impair cholesterol-dependent insulin exocytosis from pancreatic beta cells, reducing both peripheral glucose uptake and insulin secretory capacity.

ANSWER: E

Rationale:

The mechanism of statin-associated new-onset diabetes mellitus (NODM) is multifactorial and not fully elucidated, but the leading mechanistic framework involves two converging pathways: first, reduced expression of glucose transporter type 4 (GLUT4) in skeletal muscle and adipose tissue — downstream of isoprenoid depletion caused by HMG-CoA reductase inhibition, affecting small GTPase (Rho/Rac) signaling required for GLUT4 translocation to the plasma membrane — resulting in impaired insulin-stimulated peripheral glucose uptake; and second, impaired insulin secretion from pancreatic beta cells, mediated by reduced cholesterol efflux from beta cell membranes, which disrupts the calcium-dependent exocytosis machinery required for insulin granule release. Mendelian randomization studies of HMG-CoA reductase loss-of-function variants confirm that the diabetogenic risk is causally linked to HMG-CoA reductase inhibition itself and is not an off-target drug effect. The Cholesterol Treatment Trialists (CTT) Collaboration meta-analysis demonstrated that high-intensity statin therapy increases new-onset diabetes risk by approximately 12% relative to placebo, with risk concentrated in patients who already have metabolic risk factors — as in this case (metabolic syndrome, impaired fasting glucose, BMI >30).

Option A: Option A is incorrect because statins do not activate PPARγ; PPARγ agonism is the mechanism of thiazolidinediones (rosiglitazone, pioglitazone), not HMG-CoA reductase inhibitors.
Option B: Option B is incorrect because statins do not competitively inhibit glucokinase; glucose sensing in beta cells via glucokinase is not a target of HMG-CoA reductase inhibition, and the insulin secretory response is impaired by cholesterol-dependent exocytosis disruption rather than by glucokinase blockade.
Option C: Option C is incorrect because statin-associated beta cell injury is not characterized by direct mitochondrial ROS generation causing irreversible apoptosis; the mechanism is functional and reversible (cholesterol efflux impairment), and the incidence of NODM is not proportional to cumulative dose in a way consistent with cumulative apoptosis.
Option D: Option D is incorrect because SGLT2 upregulation is not a statin mechanism; SGLT2 inhibition is the mechanism of the gliflozin drug class (empagliflozin, dapagliflozin, canagliflozin), which lowers plasma glucose by increasing urinary glucose excretion — the opposite of the described effect.

6. A 68-year-old man with stage G4 chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) 22 mL/min/1.73m²), type 2 diabetes mellitus, and no prior cardiovascular events is being evaluated for statin initiation. His LDL-cholesterol is 142 mg/dL. His nephrologist references the Study of Heart and Renal Protection (SHARP) trial in recommending statin therapy. A second patient — a 71-year-old man with end-stage renal disease on maintenance hemodialysis for four years — is evaluated by the same team. Which of the following most accurately characterizes the evidence base for statin therapy in these two patients?

A) Both patients derive equivalent cardiovascular benefit from statin therapy; the SHARP trial enrolled both pre-dialysis and dialysis patients and demonstrated a significant reduction in major atherosclerotic events across both subgroups.
B) Statin therapy is contraindicated in both patients because severe renal impairment causes unpredictable statin accumulation regardless of which agent is selected, making the risk-benefit ratio unfavorable in all CKD stages G4–G5.
C) The first patient (pre-dialysis CKD) is unlikely to benefit from statin therapy because CKD-associated cardiovascular mortality is driven primarily by arrhythmia and sudden cardiac death rather than atherosclerotic events, making LDL reduction ineffective in this population.
D) The first patient (pre-dialysis CKD) has evidence of cardiovascular benefit from statin therapy based on SHARP, while the second patient (hemodialysis) does not — the 4D and AURORA trials demonstrated neutral primary endpoints in hemodialysis patients.
E) Statin therapy should be withheld from both patients until eGFR stabilizes, because progressive renal function decline alters statin pharmacokinetics unpredictably and current KDIGO guidelines recommend against initiating new statin therapy in patients with eGFR below 30 mL/min/1.73m².

ANSWER: D

Rationale:

The evidence base for statin therapy in CKD makes a clinically critical distinction between pre-dialysis CKD and patients already established on hemodialysis. The SHARP trial (Study of Heart and Renal Protection) enrolled 9,270 patients with CKD — including both pre-dialysis (approximately two-thirds) and dialysis patients — and demonstrated a 17% reduction in major atherosclerotic events in the pre-dialysis CKD subgroup treated with simvastatin 20 mg plus ezetimibe 10 mg compared to placebo. This constitutes the primary evidence base supporting statin therapy in non-dialysis CKD. In contrast, two landmark trials in hemodialysis patients — the 4D trial (Die Deutsche Diabetes Dialyse Studie), which studied atorvastatin 20 mg in hemodialysis patients with type 2 diabetes, and the AURORA trial (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis), which studied rosuvastatin 10 mg in hemodialysis patients — both demonstrated neutral primary endpoints, failing to show a significant reduction in cardiovascular events. The leading explanation is that the predominant mode of cardiovascular death in long-standing hemodialysis patients shifts from atherosclerotic events (which statin therapy targets) toward sudden cardiac death and arrhythmia (which it does not). KDIGO 2013 guidelines recommend statin therapy for CKD patients aged ≥50 years not on dialysis, supporting initiation in the first patient but not mandating it in the second.

Option A: Option A is incorrect because SHARP did not demonstrate equivalent benefit across both subgroups; the pre-dialysis subgroup drove the positive atherosclerotic event reduction, while the dialysis subgroup benefit was not significant.
Option B: Option B is incorrect because statin therapy is not contraindicated across all CKD G4–G5; most statins can be used with dose adjustment or monitoring, and rosuvastatin is capped at 10 mg for eGFR <30 rather than avoided entirely.
Option C: Option C is incorrect because it inverts the established evidence — pre-dialysis CKD patients do derive atherosclerotic cardiovascular benefit from statin therapy; it is the hemodialysis population where atherosclerotic event reduction is attenuated.
Option E: Option E is incorrect because KDIGO guidelines specifically recommend initiating statin therapy in patients with CKD not on dialysis aged ≥50 years; eGFR instability is not a contraindication to initiation, and the guideline does not recommend withholding statins pending eGFR stabilization.

7. A 31-year-old woman with heterozygous familial hypercholesterolemia (FH) has been taking rosuvastatin 20 mg daily for three years with excellent LDL-cholesterol control (LDL-C 88 mg/dL on therapy). She presents to her cardiologist to discuss pregnancy planning. She asks whether she should continue rosuvastatin throughout pregnancy. Which of the following is the most accurate and complete response?

A) Rosuvastatin should be discontinued at confirmed conception and avoided throughout pregnancy and breastfeeding; cholesterol and isoprenoid intermediates are essential for fetal organogenesis and the mevalonate pathway must not be inhibited during fetal development.
B) Rosuvastatin may be continued through the first trimester only, as organogenesis is complete by week 12 and fetal cholesterol requirements become independent of maternal statin exposure in the second and third trimesters.
C) Rosuvastatin is safe throughout pregnancy in women with FH because the cardiovascular risk of untreated hypercholesterolemia in FH outweighs the theoretical teratogenic risk, and no human teratogenicity has been definitively established for any statin.
D) Rosuvastatin should be replaced with pravastatin at conception, as pravastatin is the only statin with an FDA pregnancy safety designation and is approved for use throughout pregnancy in women with FH who cannot tolerate lipid reduction gaps.
E) Rosuvastatin should be discontinued and replaced with high-dose omega-3 fatty acids, which are the only lipid-lowering agents demonstrated to be safe in pregnancy and capable of achieving adequate LDL-C reduction in FH.

ANSWER: A

Rationale:

Statins are contraindicated in pregnancy. Current FDA labeling characterizes statins with language directing avoidance in pregnancy, reflecting both the biological rationale and the precautionary principle applied to fetal safety. The fundamental biological basis is that cholesterol and isoprenoid intermediates produced via the mevalonate pathway are essential for fetal organogenesis, central nervous system myelination, and steroidogenesis throughout gestation — not only during the first trimester. Inhibition of HMG-CoA reductase during fetal development carries theoretical teratogenic risk because these cholesterol-dependent processes occur across all three trimesters. Observational data on first-trimester statin exposure have produced mixed results — some studies suggest increased fetal anomaly risk, others show no significant excess — but the fundamental biology of the mevalonate pathway in embryogenesis justifies categorical avoidance during the entire pregnancy. Women with FH who are planning pregnancy should discontinue statin therapy at confirmed conception and remain off statins throughout pregnancy and breastfeeding; bile acid sequestrants or ezetimibe may be considered in the most severe FH cases with careful risk-benefit assessment.

Option B: Option B is incorrect because it implies fetal cholesterol dependence on maternal mevalonate pathway activity ends after the first trimester; myelination, steroidogenesis, and ongoing organogenesis continue beyond week 12, and the contraindication applies throughout pregnancy, not only the first trimester.
Option C: Option C is incorrect because clinical uncertainty about the magnitude of teratogenic risk does not override the contraindication; the absence of definitive proof of human teratogenicity does not establish safety, and the benefit-risk calculation does not favor statin continuation in pregnancy given available alternatives for the gestational period.
Option D: Option D is incorrect because no statin has an FDA approval for use in pregnancy; pravastatin does not carry a pregnancy safety designation or approval for use in pregnant women with FH — all statins share the same contraindication in pregnancy.
Option E: Option E is incorrect because omega-3 fatty acids primarily lower triglycerides, not LDL-cholesterol, and are not capable of providing adequate LDL-C reduction in a patient with familial hypercholesterolemia; they are not a substitute for statin therapy in FH and do not address the clinical question asked.

8. A 47-year-old man with HIV infection, well-controlled on a ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimen, is found to have an LDL-cholesterol of 158 mg/dL and a 10-year ASCVD risk of 9%. His infectious disease physician recommends initiating statin therapy. Which of the following statin choices is most appropriate for this patient?

A) Atorvastatin 40 mg daily — it is a high-intensity statin with proven cardiovascular outcomes data and its hepatic metabolism via cytochrome P450 3A4 (CYP3A4) is only modestly affected by ritonavir at standard doses.
B) Simvastatin 40 mg daily — simvastatin's inactive lactone prodrug form requires hepatic conversion before reaching therapeutic concentrations, which blunts the clinical impact of CYP3A4 inhibition by ritonavir.
C) Rosuvastatin 10–20 mg daily — rosuvastatin undergoes minimal CYP3A4 metabolism and its plasma exposure is not substantially increased by ritonavir-based protease inhibitor regimens, making it a preferred option in this setting.
D) Lovastatin 20 mg daily — lovastatin has the longest clinical track record among statins and its high protein binding limits the free drug fraction available for CYP3A4-mediated interaction with ritonavir.
E) Fluvastatin 80 mg XL daily — fluvastatin undergoes exclusive CYP2C9 metabolism with no CYP3A4 involvement and has been validated in randomized trials as the preferred statin in HIV patients on protease inhibitor-based regimens.

ANSWER: C

Rationale:

HIV protease inhibitors, particularly ritonavir used as a pharmacokinetic booster, are potent inhibitors of cytochrome P450 3A4 (CYP3A4). Statins that are extensively metabolized by CYP3A4 will have markedly elevated plasma concentrations — and therefore substantially increased myopathy risk — when co-administered with ritonavir-based regimens. Simvastatin and lovastatin are the most CYP3A4-dependent statins and are contraindicated with ritonavir-boosted protease inhibitors because the degree of plasma concentration elevation is sufficient to produce severe myopathy and rhabdomyolysis. Atorvastatin is also CYP3A4-metabolized and should be used at the lowest effective dose with careful monitoring rather than at standard doses. Rosuvastatin undergoes minimal CYP3A4 metabolism — its primary elimination involves sulfation and limited CYP2C9 involvement — and its plasma exposure is not substantially affected by CYP3A4 inhibition by ritonavir. Pravastatin similarly has minimal CYP3A4 involvement and is another preferred option in this setting. Rosuvastatin and pravastatin are the recommended statins in patients on CYP3A4-interactive antiretroviral therapy (ART) regimens.

Option A: Option A is incorrect because atorvastatin is a CYP3A4 substrate and ritonavir-boosted PI regimens significantly increase atorvastatin plasma concentrations; if used at all, atorvastatin must be started at the lowest dose (10 mg) with monitoring — 40 mg is not an appropriate starting dose in this context.
Option B: Option B is incorrect and dangerous: simvastatin is contraindicated with ritonavir-boosted protease inhibitors; the prodrug rationale does not protect against the interaction because CYP3A4 is involved in both the conversion and the elimination of the active acid form, and plasma concentrations reach dangerous levels.
Option D: Option D is incorrect for the same reason as B: lovastatin is also contraindicated with ritonavir-boosted PI regimens due to high CYP3A4 dependence; protein binding does not meaningfully limit the pharmacokinetic interaction at the CYP3A4 level.
Option E: Option E is incorrect because while fluvastatin does undergo primarily CYP2C9 metabolism and avoids the CYP3A4 interaction, it has not been validated in randomized trials as the preferred statin in HIV patients on PI-based regimens, and this claim overstates the evidence; rosuvastatin and pravastatin have more established use in this context.

9. A 55-year-old man underwent orthotopic heart transplantation two years ago and is maintained on cyclosporine-based immunosuppression. His lipid panel shows LDL-cholesterol of 148 mg/dL. His cardiologist wishes to initiate statin therapy. Which of the following statin choices is most appropriate, and what is the primary pharmacological reason for this selection?

A) Atorvastatin 40 mg daily — atorvastatin undergoes extensive first-pass extraction by the liver and does not require OATP1B1-mediated hepatic uptake, making it insensitive to cyclosporine's transporter inhibitory effects.
B) Simvastatin 80 mg daily — simvastatin's inactive prodrug form requires hepatic activation before systemic distribution, which limits the plasma concentration elevation caused by cyclosporine-mediated CYP3A4 inhibition.
C) Rosuvastatin 40 mg daily — rosuvastatin avoids CYP3A4 metabolism entirely and is therefore unaffected by cyclosporine's inhibition of this enzyme, permitting standard high-intensity dosing without interaction risk.
D) Lovastatin 20 mg daily — lovastatin has a shorter half-life than other statins, reducing the duration of cyclosporine-statin overlap and minimizing cumulative interaction exposure during the dosing interval.
E) Pravastatin or fluvastatin at reduced doses — these agents have the most established safety records in cyclosporine-treated transplant recipients and demonstrate the least clinically significant interaction with cyclosporine-mediated CYP3A4 and OATP1B1 inhibition.

ANSWER: E

Rationale:

Cyclosporine is a potent dual inhibitor of both cytochrome P450 3A4 (CYP3A4) and the organic anion-transporting polypeptide 1B1 (OATP1B1) hepatic uptake transporter. This dual inhibitory profile affects the systemic exposure of virtually every statin to varying degrees, making statin selection in cyclosporine-treated transplant recipients one of the most complex drug interaction decisions in clinical pharmacology. Pravastatin and fluvastatin are the preferred statins in heart transplant recipients on cyclosporine-based immunosuppression because they have the most established safety records in this specific population and demonstrate the least clinically meaningful interaction with cyclosporine. Pravastatin has low CYP3A4 dependence and relatively low OATP1B1 dependence; fluvastatin is primarily CYP2C9-metabolized. Beyond their pharmacokinetic advantages, pravastatin initiated early after cardiac transplantation has been associated in registry analyses with reduced rejection episodes and improved one-year survival — an effect attributed partly to the immunomodulatory properties of statins (reduced natural killer cell cytotoxicity, reduced MHC class II expression) in addition to lipid lowering. All statin doses should be reduced from standard in the context of cyclosporine co-administration.

Option A: Option A is incorrect because atorvastatin is both a CYP3A4 substrate and an OATP1B1 substrate; cyclosporine inhibits both pathways, substantially increasing atorvastatin plasma concentrations and myopathy risk; if used, atorvastatin must be started at low doses — 40 mg is not appropriate.
Option B: Option B is incorrect and dangerous: simvastatin is generally avoided in cyclosporine-treated recipients due to high rhabdomyolysis risk; simvastatin is extensively metabolized by CYP3A4 and its prodrug nature does not protect against the interaction — systemic exposure of the active acid form is substantially elevated by cyclosporine.
Option C: Option C is incorrect because rosuvastatin, while not CYP3A4-dependent, is an OATP1B1 substrate and cyclosporine's transporter inhibition does increase rosuvastatin plasma concentrations; rosuvastatin can be used in transplant recipients but requires dose reduction (typically starting at half the standard dose), not standard high-intensity dosing.
Option D: Option D is incorrect because lovastatin is contraindicated or strongly discouraged in cyclosporine-treated recipients due to high CYP3A4 dependence and rhabdomyolysis risk; half-life is not a meaningful protective factor against a pharmacokinetic interaction that operates at the level of metabolism and transporter uptake.

10. A 62-year-old woman with established atherosclerotic cardiovascular disease (ASCVD) has a history of bilateral proximal leg myalgia on atorvastatin 40 mg, simvastatin 20 mg, and pravastatin 40 mg — all confirmed by symptom recurrence on rechallenge and resolution on discontinuation. Her CK never exceeded 3× the upper limit of normal (ULN) during any of these episodes. Her LDL-cholesterol off statin therapy is 171 mg/dL. Her cardiologist wishes to make one further statin attempt before adding ezetimibe and considering a PCSK9 inhibitor. Which of the following represents the most pharmacologically rational next statin strategy?

A) Fluvastatin 40 mg daily — fluvastatin is a hydrophilic statin with lower skeletal muscle penetration than lipophilic agents and is therefore less likely to cause myalgia regardless of dose or dosing interval.
B) Rosuvastatin 5–10 mg every other day — rosuvastatin's long half-life of approximately 19 hours permits alternate-day dosing that achieves meaningful LDL-C reduction while reducing the frequency of peak plasma concentrations associated with muscle symptom burden.
C) Atorvastatin 10 mg daily — reduction to low-intensity dosing with a previously tolerated statin class is the preferred rechallenge strategy; pharmacogenomic and pharmacokinetic differences between atorvastatin and simvastatin are insufficient to justify switching agents.
D) Pitavastatin 4 mg daily — pitavastatin is the only statin with a demonstrated zero incidence of statin-associated muscle symptoms (SAMS) in head-to-head trials and is the guideline-recommended first choice for statin-intolerant patients.
E) Cerivastatin 0.8 mg daily — cerivastatin has the lowest reported SAMS rate of any statin at its approved dose and was withdrawn for commercial rather than safety reasons, making it a viable option for genuinely statin-intolerant patients.

ANSWER: B

Rationale:

In a patient with genuine statin-associated muscle symptoms (SAMS) on three different statins — including one hydrophilic agent (pravastatin) — at standard doses, the most pharmacologically rational next strategy exploits the unique pharmacokinetic properties of rosuvastatin: its long half-life of approximately 19 hours permits alternate-day or even twice-weekly dosing while still achieving clinically meaningful LDL-C reduction. Rosuvastatin dosed every other day can achieve approximately 20 to 35 percent LDL-C reduction — sufficient to contribute substantially to cardiovascular risk reduction in combination with ezetimibe if needed. This strategy reduces the frequency of peak plasma concentrations, which are associated with muscle symptom burden, without completely forgoing statin therapy. Rosuvastatin 5 to 10 mg every other day is a well-established rechallenge strategy for patients with prior statin intolerance at standard daily doses.

Option A: Option A is incorrect because fluvastatin is actually lipophilic (not hydrophilic); the premise of the option is factually wrong. Among lower-SAMS-rate statins, rosuvastatin, pravastatin, and pitavastatin are more commonly cited; fluvastatin's SAMS profile does not justify a specific pharmacological rationale over rosuvastatin in this context.
Option C: Option C is incorrect because this patient has already failed atorvastatin — rechallenge with the same agent at lower intensity is a reasonable general strategy, but in a patient with confirmed intolerance to atorvastatin, simvastatin, and pravastatin, switching to rosuvastatin with an alternate-day regimen offers a pharmacokinetically distinct approach not yet tried; atorvastatin dose reduction is not the most rational next step.
Option D: Option D is incorrect because pitavastatin does not have a demonstrated zero incidence of SAMS and is not guideline-recommended as the exclusive first choice for statin-intolerant patients; while pitavastatin may have a more favorable muscle symptom profile in some studies, the claim of zero SAMS incidence overstates the evidence.
Option E: Option E is incorrect because cerivastatin was withdrawn from the market in 2001 due to an unacceptably high rate of rhabdomyolysis — particularly in combination with gemfibrozil — and is not available for clinical use; it was not withdrawn for commercial reasons.

11. A 77-year-old woman with hypertension, osteoarthritis, and no prior cardiovascular events or diabetes presents for a preventive cardiology visit. Her LDL-cholesterol is 144 mg/dL and her calculated 10-year ASCVD risk is 13%. She takes no statins. Her daughter, who accompanies her, asks whether her mother should start a statin for primary prevention. The cardiologist mentions the STAREE trial. Which of the following most accurately summarizes the STAREE trial finding and its implication for this patient?

A) The STAREE trial demonstrated that rosuvastatin 40 mg significantly reduced the composite of all-cause mortality and major cardiovascular events in adults aged 70 years and older without established cardiovascular disease or diabetes, strongly supporting statin initiation in this patient.
B) The STAREE trial was terminated early due to excess non-cardiovascular adverse events in the rosuvastatin arm, including an increased rate of new-onset diabetes and cognitive decline, leading to a guideline recommendation against statin use in primary prevention in patients over 75 years.
C) The STAREE trial results do not apply to this patient because STAREE enrolled only patients with diabetes, and the absence of diabetes in this patient means her risk profile is better addressed by ACC/AHA primary prevention guidelines than by STAREE findings.
D) The STAREE trial reported no significant reduction in its primary composite outcome of disability-free survival with rosuvastatin 40 mg versus placebo in adults aged 70 years and older without established cardiovascular disease or diabetes, adding nuance to primary prevention statin decisions in elderly patients.
E) The STAREE trial demonstrated that moderate-intensity statin therapy (rosuvastatin 10 mg) was superior to high-intensity therapy (rosuvastatin 40 mg) in adults over 70 for primary prevention, establishing a dose-selection principle that directly applies to this patient.

ANSWER: D

Rationale:

The STAREE trial (Statins in Reducing Events in the Elderly) was a randomized, placebo-controlled trial of rosuvastatin 40 mg versus placebo in adults aged 70 years and older without established cardiovascular disease or diabetes — a population closely matching this patient. Results reported in 2024 showed no statistically significant reduction in the primary composite outcome of disability-free survival (a composite of death or development of dementia or persistent physical disability) in the overall primary prevention population assigned to rosuvastatin compared to placebo. This result adds clinically important nuance to the question of primary prevention statin initiation in elderly patients: while the evidence base for secondary prevention in patients aged ≥75 years supports continuing or initiating high-intensity statin therapy based on high absolute cardiovascular risk, primary prevention decisions in elderly patients involve greater uncertainty and should incorporate shared decision-making that accounts for life expectancy, frailty, comorbidity burden, polypharmacy risk, and patient preferences. For this patient, a reasonable approach is moderate-intensity statin therapy after an informed discussion that acknowledges the STAREE findings and individualizes the benefit-risk assessment.

Option A: Option A is incorrect because it inverts the STAREE result — the trial did not demonstrate a significant reduction in its primary endpoint; the finding was neutral in the primary prevention elderly population.
Option B: Option B is incorrect because STAREE was not terminated early for adverse events; it completed its planned follow-up and reported a primary neutral outcome, and no guideline has issued a recommendation against statin use over age 75 based on STAREE.
Option C: Option C is incorrect because STAREE specifically excluded patients with established CVD and diabetes — the same exclusion criteria that apply to this patient; the STAREE population is directly applicable to her.
Option E: Option E is incorrect because STAREE used only the rosuvastatin 40 mg dose versus placebo; it was not a dose-comparison trial and did not test rosuvastatin 10 mg as an arm; no dose-superiority conclusion can be drawn from the trial design.